Literature DB >> 7897241

A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells.

D Flieger1, R Gruber, G Schlimok, C Reiter, K Pantel, G Riethmüller.   

Abstract

Monocyte/macrophage-mediated cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) are slow processes, requiring cocultivation of effector and target cells for up to several days. Because of the high spontaneous release and possible reutilization of isotopic labels, the conventional radioactive release assays are unsuited for measuring long term cytotoxicity. We developed a non-radioactive flow cytometric assay for the quantitative analysis of cell-mediated cytotoxicity. Because dead cells can dissolve and disappear during the incubation period (lysis, phagocytosis), we determined the absolute numbers of living cells in the well. Prior to incubation the effector cells are stained with the red lipophilic fluorescent dye PKH26 and the target cells with the green fluorescent dye PKH2. At the end of the incubation (1-6 days) a defined number of bright fluorescent cell standards and propidium iodide for staining of dead cells was added to each well. Using flow cytometric analysis, we determined the ratio of targets to standards and calculated the absolute target cell number by multiplication with the known number of standards added. The main advantages of the assay are the possibility of extended incubation periods, the avoidance of radioactivity and its potential applicability to autologous culture systems, where effector and tumor cells are derived from the same patient. The assay opens new avenues for preclinical testing of tumor therapeutics such as monoclonal antibodies and/or cytokines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897241     DOI: 10.1016/0022-1759(94)00293-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  A real-time digital bio-imaging system to quantify cellular cytotoxicity as an alternative to the standard chromium-51 release assay.

Authors:  Julien Fassy; Kyriaki Tsalkitzi; Emie Salavagione; Nedra Hamouda-Tekaya; Véronique M Braud
Journal:  Immunology       Date:  2017-01-19       Impact factor: 7.397

2.  A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective.

Authors:  Alexis Rossignol; Véronique Bonnaudet; Béatrice Clémenceau; Henri Vié; Laurent Bretaudeau
Journal:  MAbs       Date:  2017-02-08       Impact factor: 5.857

3.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

4.  A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function.

Authors:  Cedar H Baik; Mallory Geer; Olivia K Travis; Denise C Cornelius
Journal:  J Vis Exp       Date:  2019-06-02       Impact factor: 1.355

Review 5.  New flow cytometric assays for monitoring cell-mediated cytotoxicity.

Authors:  Liubov Zaritskaya; Michael R Shurin; Thomas J Sayers; Anatoli M Malyguine
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

Review 6.  A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome.

Authors:  Natalie Eaton-Fitch; Stanley du Preez; Hélène Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  Syst Rev       Date:  2019-11-14

7.  A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry.

Authors:  Srinivas S Somanchi; Kelsey J McCulley; Anitha Somanchi; Leo L Chan; Dean A Lee
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

8.  Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay.

Authors:  Mobin A Karimi; Eric Lee; Michael H Bachmann; Ana Maria Salicioni; Edward M Behrens; Taku Kambayashi; Cynthia L Baldwin
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

9.  Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.

Authors:  Natalie Eaton; Hélène Cabanas; Cassandra Balinas; Anne Klein; Donald Staines; Sonya Marshall-Gradisnik
Journal:  BMC Pharmacol Toxicol       Date:  2018-03-27       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.